CL-316,243, a beta3-specific adrenoceptor agonist, enhances insulin-stimulated glucose disposal in nonobese rats - PubMed (original) (raw)
Comparative Study
. 1997 Aug;46(8):1257-63.
doi: 10.2337/diab.46.8.1257.
Affiliations
- PMID: 9231648
- DOI: 10.2337/diab.46.8.1257
Comparative Study
CL-316,243, a beta3-specific adrenoceptor agonist, enhances insulin-stimulated glucose disposal in nonobese rats
C J de Souza et al. Diabetes. 1997 Aug.
Abstract
Administration of the murine-selective beta3 adrenoceptor agonist CL-316,243 corrects obesity and elevated blood glucose in diabetic rodents. This antiobesity effect is attributed to an increase in the thermogenic activity of brown adipose tissue (BAT). The antidiabetic effect is unknown, but has been attributed to the decline in body weight and plasma free fatty acids (FFAs). This study using the euglycemic-hyperinsulinemic clamp method was performed in nonobese, nondiabetic Sprague-Dawley rats fed normal rodent chow to determine if the beta3 agonist could improve insulin sensitivity and/or responsiveness in the absence of weight loss or lowering of circulating FFAs. Subcutaneous miniosmotic pumps delivered either saline to control or 1 mg x kg(-1) x day(-1) of CL-316,243 for 10-12 days. Fed plasma glucose, insulin, and FFA levels were similar between the groups. Significant increases in food consumption, resting metabolic rates, and body core temperatures occurred, but only after 7 days of treatment. A 14% decrease in the respiratory quotient was also observed. Plasma glucose and insulin excursions in response to an oral glucose load (2 g/kg) on day 11 were unaltered. Cl-316,243 treatment resulted in a decrease in abdominal and epididymal white fat pad weights, while interscapular brown adipose tissue (IBAT) weight doubled. Basal and insulin-stimulated whole-body glucose disposal rates were increased, while hepatic glucose output was suppressed to a greater extent in the CL-316,243 animals after 10 days of uninterrupted treatment. Chronic treatment with CL-316,243 resulted in an increase in basal and insulin-stimulated [3H]2-deoxyglucose (2-DG) uptake by the retroperitoneal and epididymal white tissue and IBAT, but skeletal muscle 2-DG uptake under the same conditions was unaltered. These studies demonstrate that treatment with CL-316,243 improves basal and insulin-stimulated glucose disposal, and these effects occurred in the absence of a decrease in body weights and FFA concentrations. A particularly interesting observation was that the tissues responsible for this effect were white and brown adipose tissue, while skeletal muscle remained unaffected.
Similar articles
- Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans.
Weyer C, Tataranni PA, Snitker S, Danforth E Jr, Ravussin E. Weyer C, et al. Diabetes. 1998 Oct;47(10):1555-61. doi: 10.2337/diabetes.47.10.1555. Diabetes. 1998. PMID: 9753292 Clinical Trial. - Activation of β3-adrenoceptors increases in vivo free fatty acid uptake and utilization in brown but not white fat depots in high-fat-fed rats.
Warner A, Kjellstedt A, Carreras A, Böttcher G, Peng XR, Seale P, Oakes N, Lindén D. Warner A, et al. Am J Physiol Endocrinol Metab. 2016 Dec 1;311(6):E901-E910. doi: 10.1152/ajpendo.00204.2016. Epub 2016 Oct 25. Am J Physiol Endocrinol Metab. 2016. PMID: 27780820 Free PMC article. - beta(3)-Adrenoceptor agonists: potential, pitfalls and progress.
Arch JR. Arch JR. Eur J Pharmacol. 2002 Apr 12;440(2-3):99-107. doi: 10.1016/s0014-2999(02)01421-8. Eur J Pharmacol. 2002. PMID: 12007528 Review. - Substrate competition and insulin action in animal models.
Vettor R, Lombardi AM, Fabris R, Serra R, Pagano C, Macor C, Federspil G. Vettor R, et al. Int J Obes Relat Metab Disord. 2000 Jun;24 Suppl 2:S22-4. doi: 10.1038/sj.ijo.0801271. Int J Obes Relat Metab Disord. 2000. PMID: 10997602 Review.
Cited by
- Role of adipocyte browning in prostate and breast tumor microenvironment.
Ku HC, Cheng CF. Ku HC, et al. Tzu Chi Med J. 2022 Jun 27;34(4):359-366. doi: 10.4103/tcmj.tcmj_62_22. eCollection 2022 Oct-Dec. Tzu Chi Med J. 2022. PMID: 36578640 Free PMC article. Review. - Rutaecarpine Promotes Adipose Thermogenesis and Protects against HFD-Induced Obesity via AMPK/PGC-1α Pathway.
Chen D, Duan Y, Yu S, Zhang X, Li N, Li J. Chen D, et al. Pharmaceuticals (Basel). 2022 Apr 13;15(4):469. doi: 10.3390/ph15040469. Pharmaceuticals (Basel). 2022. PMID: 35455466 Free PMC article. - Repurposing beta-3 adrenergic receptor agonists for Alzheimer's disease: beneficial effects in a mouse model.
Tournissac M, Vu TM, Vrabic N, Hozer C, Tremblay C, Mélançon K, Planel E, Pifferi F, Calon F. Tournissac M, et al. Alzheimers Res Ther. 2021 May 21;13(1):103. doi: 10.1186/s13195-021-00842-3. Alzheimers Res Ther. 2021. PMID: 34020681 Free PMC article. - The cellular and functional complexity of thermogenic fat.
Cohen P, Kajimura S. Cohen P, et al. Nat Rev Mol Cell Biol. 2021 Jun;22(6):393-409. doi: 10.1038/s41580-021-00350-0. Epub 2021 Mar 23. Nat Rev Mol Cell Biol. 2021. PMID: 33758402 Free PMC article. Review. - β-adrenergic receptor signaling evokes the PKA-ASK axis in mature brown adipocytes.
Hattori K, Wakatsuki H, Sakauchi C, Furutani S, Sugawara S, Hatta T, Natsume T, Ichijo H. Hattori K, et al. PLoS One. 2020 Oct 27;15(10):e0232645. doi: 10.1371/journal.pone.0232645. eCollection 2020. PLoS One. 2020. PMID: 33108364 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical